Showing 91 - 100 of 397,139
External reference pricing (ERP), the practice of benchmarking domestic drug prices to foreign prices, generates an incentive for firms to withhold products from low-income countries. Using a novel moment inequality approach, we estimate a structural model to measure the extent to which ERP...
Persistent link: https://www.econbiz.de/10014093683
the application of biotechnology to drug development as well as firms that specialize in low-cost production of off-patent …
Persistent link: https://www.econbiz.de/10014025576
We study the patent strategy of pharmaceutical firms in reaction to the threat of generic entry. Estimating difference … drugs, these drugs have remaining patent protection, and in order to protect new chemical entities …
Persistent link: https://www.econbiz.de/10013310520
Persistent link: https://www.econbiz.de/10003884405
Persistent link: https://www.econbiz.de/10009581545
Persistent link: https://www.econbiz.de/10011476934
In agreements settling patent challenges in the drug industry, the plaintiff brand commonly licenses the defendant … generic to sell prior to patent expiry. Some agreements require the generic to pay the brand royalties. Despite the …
Persistent link: https://www.econbiz.de/10014247939
This paper examines the role of regulation and competition in generic markets. Generics offer large potential savings to payers and consumers of pharmaceuticals. Whether the potential savings are realized depends on the extent of generic entry and uptake and the level of generic prices. In the...
Persistent link: https://www.econbiz.de/10013122264
Persistent link: https://www.econbiz.de/10011700714